Tempo Raises $220M in New Capital to Enhance AI & 3D Sensor Technology

Tempo the first home fitness system that uses advanced 3D sensors and AI to analyze users’ motion to provide a personal training experience—today announced $220 million in new funding.

Tempo notes the Series C round was led by SoftBank Vision Fund 2* with participation from new investor Steadfast Capital Ventures, and returning investors DCM, General Catalyst, Norwest Venture Partners, and Bling Capital. This brings Tempo’s funding to date to nearly $300 million.

Tempo will allocate the new funding toward the continued enhancement of its AI and 3D sensor technology to further expand its cutting-edge, real-time form feedback and personal guidance for users. The company also recently announced vast expansions across its hardware, software, and content offerings to best supplement the training experience and continue to deliver a full, at-home gym and personal trainer experience.

“Tempo was launched on the premise that the most advanced and versatile technology can unlock human potential by redefining the personal training experience. Today, our AI uses 3D sensors and is trained on over 5M workouts over 40K hours to give our users the most effective and personalized workouts possible,” said Moawia Eldeeb, Co-Founder and CEO of Tempo. “This new funding allows Tempo to further develop its AI to expand our class categories and content offerings.”

With its unique offering for at-home fitness, Tempo has gained significant momentum since launching in 2020. In the past year alone, Tempo saw its sales increase by 10 times and has seen 0% subscription cancellation.

“The fitness landscape has transformed dramatically as more consumers seek home fitness solutions. By providing personalized AI generated feedback through its computer vision technology, Tempo delivers the experience of working out with a personal trainer to consumers in their homes,” said Jeff Housenbold, Managing Partner, SoftBank Investment Advisers. “We’re excited to partner with Moawia and the Tempo team to support their ambition to help people progress in their fitness journeys at home.”

As the only complete yet incomparably compact and connected home training solution on the market, the Tempo Studio combines the hands-on guidance of a personal trainer, the motivation of a group fitness class, and premium design-forward equipment. After more than six years of developing Tempo’s flagship product, the company remains dedicated to providing the most efficient and personalized fitness experience to its community.

SourceTempo
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy